Levamisole in systemic lupus erythematosus.
Two patients with systemic lupus erythematosus complicated with lupus nephritis were treated with levamisole, an immunomodulator. Clinical features, including urinary protein excretion and creatine clearance, were restored in one patient, also immunoparameters such as ANA, Ig-bearing cell number and PHA-skin test. The other patient did not respond to levamisole but did respond to cyclophosphamide.
D000293:Adolescent; D000906:Antibodies; D000974:Antibodies, Antinuclear; D003520:Cyclophosphamide / Q000627:therapeutic use; D004247:DNA / Q000276:immunology; D005260:Female; D006561:Herpes Simplex / Q000150:complications; D006801:Humans; D007978:Levamisole / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy*; D008213:Lymphocyte Activation; D009393:Nephritis / Q000150:complications; D011239:Prednisolone / Q000627:therapeutic use; D012397:Rosette Formation
D000906:Antibodies; D000974:Antibodies, Antinuclear; D007978:Levamisole; D003520:Cyclophosphamide; D004247:DNA; D011239:Prednisolone